<DOC>
	<DOCNO>NCT01858155</DOCNO>
	<brief_summary>This study evaluate dose escalation melatonin pediatric oncology patient relapse solid tumor . The purpose study determine safety melatonin dose 20 mg daily , well determine maximum tolerate dose melatonin .</brief_summary>
	<brief_title>Phase I Dose Finding Study Melatonin Pediatric Oncology Patients With Relapsed Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Melatonin</mesh_term>
	<criteria>Patients must able take medication mouth either swallowing , chew sublingual route . Patients must document life expectancy ≥ 8 week . Patients must histologic radiographic evidence relapse malignant solid tumor . Intrinsic brain stem tumor optic pathway glioma may diagnose clinical radiologic method . Patient , parent , legal representative and/or guardian must sign write informed consent . Assent , appropriate , obtain accord institutional guideline . Minimum Weight Requirements : Dose level 1 22.2kg , Dose level 2 11.1kg , Dose level 3 5.6kg Patients must take stable dose ( addition , modification deletion ) chemotherapy start ≥ 14 day prior study enrollment . Prescribed Chemotherapy drug ( ) must know interact melatonin Adequate Bone Marrow Function Defined : 1 . Patients solid tumor without bone marrow involvement : Peripheral absolute neutrophil count ( ANC ) ≥ 1 x109/L Platelet count ≥ 50 X 109/L ( transfusion independent , define receive platelet transfusion within 7 day period prior enrollment ) Hemoglobin ≥ 80 g/L ( may receive RBC transfusion ) 2 . Patients know bone marrow metastatic disease eligible study evaluable hematologic toxicity . Must known refractory red cell platelet transfusion . These patient need meet bone marrow function requirement , hematological toxicity measure due metastatic disease . Adequate Liver Function Defined : Total Bilirubin ≤ 1.5 x upper limit normal ( ULN ) age . ALT ≤ 1.5 x ULN age . Chemotherapy : Melatonin inhibit action doxorubicin Growth factor support white cell number administer ≤ 7 day prior enrollment . Patients require corticosteroid stable decrease dose corticosteroid ≥ 14 day . Patients prescribed immunosuppressant therapy specifically utilized chemotherapy purpose . Patient prescribed : Cyclosporine , Mycophenolate Mofetil HCL , Tacrolimus , Sirolimus Azathioprine exclude Patients prescribed anticoagulation therapy ( Warfarin , Low Molecular Weight Heparin ( LMWH ) , System Heparin Therapy ) Concomitant medication know CYP1A2 inhibitor interact Melatonin . Patients prescribed megace , corticosteroid periactin start ≤ 14 day prior study enrollment . Patients take following medication : benzodiazepine , nifedipine , NSAID 's , ASA and/or Beta Blockers Patients ≤ 7 day postoperative surgical procedure . Patients sign active postoperative bleeding . Patients infection respond antimicrobial therapy . Any condition would negatively impact effective gut absorption and/or swallow study medication . Patients opinion investigator may able comply study protocol requirement Patients already receive melatonin exclude study . Allergies medicinal and/or nonmedicinal ingredient melatonin include : Melatonin , Calcium Salicate , Croscarmellose Sodium , IsoMalt , Magnesium Stearate , Microcrystalline Cellulose . As melatonin cause fatigue , patient take melatonin refrain drive operate machinery within 5 hour take melatonin .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>